home / stock / mnpr / mnpr quote
Last: | $0.7201 |
---|---|
Change Percent: | -0.94% |
Open: | $0.71 |
Close: | $0.7201 |
High: | $0.73389 |
Low: | $0.701 |
Volume: | 52,417 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.7201 | $0.71 | $0.7201 | $0.73389 | $0.701 | 52,417 | 07-05-2024 |
$0.7034 | $0.712 | $0.7034 | $0.73 | $0.7 | 54,133 | 07-04-2024 |
$0.7034 | $0.712 | $0.7034 | $0.73 | $0.7 | 54,133 | 07-03-2024 |
$0.72 | $0.73 | $0.72 | $0.7568 | $0.711 | 45,296 | 07-02-2024 |
$0.7414 | $0.76 | $0.7414 | $0.76 | $0.7101 | 76,915 | 07-01-2024 |
$0.7301 | $0.733 | $0.7301 | $0.769 | $0.71 | 96,120 | 06-28-2024 |
$0.7425 | $0.735 | $0.7425 | $0.767 | $0.735 | 90,315 | 06-27-2024 |
$0.7455 | $0.7926 | $0.7455 | $0.7926 | $0.7378 | 68,634 | 06-26-2024 |
$0.82 | $0.83 | $0.82 | $0.8689 | $0.78 | 100,516 | 06-25-2024 |
$0.799 | $0.712 | $0.799 | $0.81 | $0.701 | 149,088 | 06-24-2024 |
$0.6902 | $0.669 | $0.6902 | $0.726 | $0.6601 | 107,157 | 06-21-2024 |
$0.673 | $0.8003 | $0.673 | $0.831 | $0.6511 | 516,060 | 06-20-2024 |
$0.827 | $0.9 | $0.827 | $0.914 | $0.82 | 122,795 | 06-19-2024 |
$0.827 | $0.9 | $0.827 | $0.914 | $0.82 | 122,795 | 06-18-2024 |
$0.86 | $0.92 | $0.86 | $0.941 | $0.8541 | 95,679 | 06-17-2024 |
$0.94 | $0.959 | $0.94 | $0.9639 | $0.883501 | 117,140 | 06-14-2024 |
$0.9143 | $0.9 | $0.9143 | $1.08 | $0.85 | 519,561 | 06-13-2024 |
$0.8949 | $0.8211 | $0.8949 | $0.9 | $0.800101 | 112,632 | 06-12-2024 |
$0.815 | $0.7614 | $0.815 | $0.829 | $0.751 | 54,744 | 06-11-2024 |
$0.7746 | $0.8388 | $0.7746 | $0.849 | $0.75 | 130,183 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...
WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead...